• FDA clears Celltrion, Teva's biosimilar version of Roche's Herceptin firstwordpharma
    December 17, 2018
    Celltrion and Teva announced that the FDA has approved Herzuma (trastuzumab-pkrb), a biosimilar referencing Roche's Herceptin (trastuzumab), for the treatment of certain patients with HER2-overexpressing breast cancer. Specifically, Herzuma was cleared fo
PharmaSources Customer Service